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Case presentation
This 68-year-old black male has had sickle cell disease since
childhood and has suffered the typical sickle cell crises that are
characterized primarily by bone pain. The patient's longevity is
probably attributable to a high percentage of fetal hemoglobin—
65% hemoglobin SS by electrophoresis. From age 25, he under-
went blood transfusion at approximately 6-month intervals,
maintaining a hematocrit of approximately 30%. Sickle cell
crises, managed with analgesics and hydration, occurred I to 2
times per year from age 25 to his most recent admission. From
ages 28 to 30, the patient developed leg ulcers and acute chole-
cystitis for which he underwent a sympathectomy and a chole-
cystectomy, respectively. At age 30, he developed tophaceous
gout, which was managed with probenecid. Laboratory findings
at that time included a serum uric acid of 10.8 mg/dl and a serum
urea nitrogen of 16 mg/dl. A marked defect in urinary concentra-
tion—Umax = 320 mOsm/kg—was observed following a 12-hour
overnight dehydration test. At age 40, the patient developed an-
gina pectoris as well as congestive heart failure and peripheral
edema; his blood pressure was 170/100 mm Hg, and cardiomega-
ly was evident on chest x-ray. The patient was started on a regi-
men of digitalis and diuretics.
At age 63, the patient was hospitalized with a myocardial in-
farction and congestive heart failure. Hypertension with a blood
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pressure of 200/100 mm Hg and cardiomegaly again were pres-
ent. Hyperkalemia was documented for the first time with a
serum potassium concentration of 5.7 mEq/liter. Other laborato-
ry findings were: serum sodium, 141 mEq/Iiter; serum chloride,
104 mEq/liter; serum bicarbonate, 24 mEq/liter; serum creatinine,
1.4 mg/dl; serum urea nitrogen, 26 mg/serum uric acid, 112
mg/dl. Results of urinalysis revealed: 10 to 12 white blood cells
(WBC) per high-power field (HPF); 5 to 10 red blood cells (RBC)
per HPF; and proteinuria (3+). Urine culture was negative. Over
the next 3 years, the patient was hospitalized on numerous oc-
casions for congestive heart failure, chest pain, leg ulcers, and
gout; he was treated with digoxin, furosemide, a-methyldopa,
colchicine, and occasionally indomethacin. During this time, the
serum potassium concentration never fell below 6 mEq/liter and
ranged as high as 7.8 mEq/Iiter. Because of the persistently high
serum potassium concentration, the patient was admitted to the
clinical research center for further diagnostic evaluation.
On admission, the physical examination revealed the follow-
ing: blood pressure, 200/100 mm Hg; pulse, 84/mm and regular;
respirations, 16/mm; temperature, 37° C. The skin showed old
ulcer disease and stasis dermatitis; the optic fundi had moderate
arteriolar narrowing and arteriovenous nicking without hemor-
rhages or exudates; the neck veins were distended 6 cm above
the clavicle at 45°. Moist rales were heard one-third of the way
up both lung fields posteriorly; the point of maximal impulse was
diffuse in the 6th to 7th intercostal interspaces and 15 cm to the
left of the midsternal line; S3 and S4 gallops were present; a
Grade IIIIVl systolic ejection murmur was heard at the base
and radiated to the lower left sternal border. Abdominal exami-
nation revealed no organomegaly or tenderness. Rectal examina-
tion was normal and the prostate was enlarged (1+). Examina-
tion of the extremities revealed markedly diminished peripheral
pulses, tophi over both elbows, and deforming arthritis of the
hands and big toes, which had been affected previously with
gout. Neurologic examination was unremarkable except for ab-
sent reflexes in the lower extremities and decreased sensation
below the knees.
Laboratory findings included the following: hematocrit, 28%;
WBC, 6800 with a normal differential; reticulocyte count, 1.2%;
serum potassium. 7.2 mEq/liter, with a simultaneous plasma po-
tassium of 6.8 mEq/liter; serum sodium, 140 mEqlliter serum chlo-
ride, 109 mEq/liter serum bicarbonate, 19 mEq/liter; serum urea
nitrogen, 39 mg/dl serum creatinine, 2 mg/dl serum uric acid, II 8
mg/dl serum calcium, 9 mg/dl serum phosphate, 4.7 mg/dl; blood
pH, 7.33; carbon dioxide tension, 31 mm Hg; a simultaneous
urine pH obtained under oil. 5.1; 24-hour urine protein excretion,
2.4 grams; 24-hour urine uric acid excretion, 500 mg; creatinine
clearance, 35 mI/mm. Results of urinalysis revealed; 2 to 5 WBC
/HPF; 5 to 10 RBC/HPF. A urine culture was negative. Liver
function studies were normal and glucose concentration while
fasting was 105 mg/dl. A chest radiogram revealed marked
cardiomegaly with redistribution of blood flow to the upper
lobes. An electrocardiogram revealed evidence of an old anterior
myocardial infarction and nonspecific ST-T wave changes.
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Additional studies were performed to define the mechanism of
the hyperkalemia and these findings will be discussed.
Discussion
Dr. Ralph A. DeFronzo (Associate Professor of
Medicine, Yale University School of Medicine,
New Haven, Connecticut): This 68-year-old black
man is the oldest known living patient with sickle
cell disease. Today I plan to discuss only one of
his renal and electrolyte problems—hyperkalemia.
A full understanding of the etiology and manage-
ment of this patient's severe hyperkalemia requires
a brief review of the normal renal handling of po-
tassium.
Renal potassiuFn handling. Recent studies in-
dicate that the majority of the potassium excreted in
the urine is derived from secretion in the distal tu-
bule and collecting duct [1-3]. Although approxi-
mately 600 to 700 mEq of potassium are filtered dai-
iy by the glomerulus, most potassium is reabsorbed
proximally and only approximately 10% remains by
the early distal tubule. This fraction remains fixed
despite a variety of maneuvers that are known ei-
ther to increase or decrease the rate of urinary po-
tassium excretion. Approximately 60% of the fil-
tered potassium load is reabsorbed by the acces-
sible portion of the proximal convoluted tubule, and
an additional 25% to 30% has been reabsorbed by
the time the fluid reaches the first accessible seg-
ment of the distal tubule. Although some potassium
may be added to the tubular fluid by the ascending
loop of Henle [3], the mid-to-late distal convoluted
tubule is the first major site of potassium secretion
[1—3]. Cells of the cortical collecting duct are mor-
phologically similar to those of the distal tubule; it is
not surprising therefore that this segment of the col-
lecting duct is also capable of net potassium secre-
tion [3, 4]. Although the contribution of the medul-
lary collecting duct to final potassium excretion re-
mains uncertain, several recent studies have
indicated an important role of this nephron segment
in renal potassium excretion [5—7].
Figure 1 illustrates a model depicting distal tubu-
lar potassium secretion using data gathered from
micropuncture, microperfusion, and other tech-
niques [3, 8]. This model contains several salient
features. (1) The luminal membrane is electronega-
tive by approximately 50 mV as compared with the
pericapillary membrane. (2) An active pump located
in the pericapillary membrane transfers potassium
into the cell against a large concentration gradient.
Once within the cell, the potassium either back dif-
fuses into the capillary blood or enters the tubular
lumen, but the electrical gradient, which is lumen
negative, favors the net secretion of potassium into
the tubular fluid. (3) The transport of potassium by
the active pump is coupled in some loose fashion to
sodium transport, and the activity of the pump ap-
pears to be influenced by the enzyme sodium-potas-
sium ATPase. (4) The pump system is dependent on
the presence of aldosterone and in the absence of
this hormone the ability to secrete potassium is
markedly impaired. (5) The activity of the pump is
exquisitely sensitive to small changes in the potas-
sium concentration in the pericapillary blood: hy-
perkalemia provides a potent stimulus to enhanced
potassium uptake by the distal tubular cell. Once
inside the cell, potassium passively diffuses down
the electrochemical gradient into the tubular fluid.
(6) An increase in sodium delivery alone and an in-
crease in urine flow independent of sodium delivery
stimulate potassium excretion [9]. (7) The activity
of the pump is strongly influenced by changes in
acid-base status: acute acidosis inhibits, and acute
alkalosis stimulates, potassium secretion. (8) A po-
tassium reabsorptive mechanism also must exist in
the distal tubule because urinary potassium excre-
tion can approach zero under conditions of severe
dietary potassium restriction despite delivery of 5%
to 10% of the filtered load to the early distal tubule.
The pathophysiology of the clinical disorders
complicated by impaired potassium secretion and,
consequently, hyperkalemia follows directly from
this model of renal potassium handling. Thus, de-
creased renal excretion of potassium and the poten-
tial for hyperkalemia can result from inadequate so-
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Fig. 1. Sche,natic representation ofpotassium secretion by the
distal tubule.
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dium delivery to the distal nephron; decreased urine
flow; a defect in the renin-angiotensin-aldosterone
axis; a primary tubular secretory defect; inhibition
of the potassium pump; or the presence of renal dis-
ease, which directly affects the integrity of the po-
tassium secretory cells located in the distal neph-
ron.
Differential diagnosis of sustained hyperkalernia.
The search for the cause of hyperkalemia can be
approached in a logical sequence. Table I lists nine
general causes of increased serum potassium levels.
Before initiating an extensive investigation, facti-
tious causes should be excluded. In the patient pre-
sented today, laboratory error was excluded by
repeated plasma determinations. "Pseudohyperka-
lemia" was excluded by the observation that simul-
taneous determinations of potassium concentration
in serum and plasma agreed within 0.2 mEq/liter
and by the normal white blood cell and platelet
counts. Acute acidemia is a well-known cause of
true hyperkalemia [10]. Two mechanisms are in-
volved: first, acute acidemia inhibits renal potas-
Table 1. Etiology of hyperkalemia
I. Factitious
I. Laboratory error
2. 'Pseudohyperkalemia' —in vitro hemolysis, throm-
bocytosis, leukocytosis
II. Acidemia (Acute)
I1I.Increased input
1. Exogenous: diet, salt substitutes, low-sodium diet,
medications
2. Endogenous: hemolysis, 01 bleeding, catabolic
states, crush injury
IV. Inadequate distal delivery of sodium and decreased distal
tubular flow
V. Renal failure
1. Acute
2. Chronic: GFR < 15-20 mI/mm
VI. Impaired renin-aldosterone axis
I. Addison's disease
2. Enzyme deficiency
3. Primary hypoaldosteronism
4. Primary hyporenmnism
5. Angiotensin deficiency or insensitivity
6. Other (prostaglandin deficiency)
VII. Primary renal tubular potassium secretory defect
I. Systemic lupus erythematosus
2. Sickle cell disease
3. Post-renal transplantation
4. Amyloidosis
5. Congenital (children with short stature)
6. Familial
VIII. Inhibition of tubular secretion
I. Spironolactone
2. Triamterene
3. Amiloride
4. Digitalis
IX. Abnormal potassium distribution
1. Insulin deficiency
2. Aldosterone deficiency
sium secretion [3]; second, as acidosis develops,
hydrogen ions move into cells and this shift is asso-
ciated with an efflux of potassium from cells. Since
hyperkalemia was present in this patient when the
blood pH and plasma bicarbonate concentration
were normal, the disturbance in potassium homeo-
stasis cannot be related to an acid-base disorder.
Increased input of potassium, from either exoge-
nous or endogenous sources, can also result in hy-
perkalemia, but the rise in plasma potassium con-
centration is usually transient unless an underlying
defect in renal potassium excretion is present as
well [11]. During sustained intravenous potassium
chloride infusion, the plasma potassium concentra-
tion can rise into the 5.0 to 5.4 mEq/liter range ini-
tially, but it returns to normal within 24 to 36 hours
because of enhanced renal potassium excretion and
increased cellular influx of potassium [12, 13].
Thus, the persistence of hyperkalemia even in the
face of an increased potassium load should suggest
an underlying defect in the potassium homeostatic
system. In the patient under discussion, no obvious
cause of excess potassium input was discernible
and, of course, hyperkalemia was sustained for long
periods of time.
Diminished sodium delivery to the distal sites of
potassium secretion is commonly cited as a cause of
hyperkalemia. However, this explanation is not suf-
ficient unless urinary sodium excretion markedly
falls to levels below 10 to 20 mEq/day; sodium de-
livery to the distal tubule, the major site of potas-
sium secretion, is rarely rate-limiting, even when
dietary sodium intake is markedly reduced [3]. Fur-
thermore, recent studies suggest that flow, rather
than sodium delivery, may be the primary determi-
nant of potassium secretion [9]. In the patient we
are discussing, neither decreased sodium excretion
nor decreased urine flow were present and thus can-
not account for the development of hyperkalemia.
The patient did have moderate chronic renal in-
sufficiency secondary to a combination of 'sickle
cell" kidney disease, nephrosclerosis, gouty ne-
phropathy, and as we will see later, mesangiocapil-
lary glomerulonephritis. However, it is uncommon
for a patient with chronic renal failure to have hy-
perkalemia unless the glomerular filtration rate is
less than 10 to 15 mllmin. Such patients are pro-
tected from hyperkalemia by a remarkable adaptive
increase in potassium secretion by the remaining
renal tubular cells [13—15], enhanced gastrointesti-
nal potassium secretion [16], and increased move-
ment of potassium into tissues [17, 18].
None of the previously discussed abnormalities
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can explain this patient's hyperkalemia; one must
consider therefore the possibility of either a defect
in the renin-angiotensin-aldosterone axis or a pri-
mary tubular potassium secretory defect. In pre-
viously published studies from our laboratory, we
demonstrated impaired potassium excretion in pa-
tients with sickle cell disease who had normal al-
dosterone secretion [19]. Thus, on a priori grounds,
a primary defect in renal tubular potassium secre-
tion seemed the most likely cause of hyperkalemia
in this patient. We studied 6 patients with sickle cell
disease who ranged in age between 19 and 37 years;
all were normokalemic and had normal inulin and
para-aminohippurate clearances. In these individ-
uals, the increase in urinary potassium excretion
following the intravenous administration of potas-
sium chloride, furosemide, and sodium sulfate was
markedly impaired. This impairment occurred de-
spite normal basal aldosterone levels and a normal
plasma aldosterone response to volume contrac-
tion, ambulation, ACTH, and angiotensin II [19].
Impaired potassium secretion in the presence of an
intact renin-aldosterone axis is evidence of a renal
tubular defect in potassium secretion. The inability
to augment potassium excretion after intravenous
sodium sulfate administration is particularly charac-
teristic of a renal tubular secretory defect. Delivery
of the impermeant sulfate anion, which significantly
increases the negativity within the lumen, markedly
increases potassium secretion in normal individ-
uals, and this stimulatory effect, although some-
what blunted, persists in the absence of aldosterone
[20, 21]. Despite these findings, clinically significant
hyperkalemia is an exceptional occurrence in pa-
tients with sickle cell disease [22]. On the basis of
histologic changes in the papilla and medulla [5—7],
however, one might anticipate that hyperkalemia
would occur if such patients lived long enough for
the renal lesion to progress.
To examine whether a tubular defect in potas-
sium secretion was present in this patient, he was
given an intravenous infusion of sodium sulfate (1.8
mmoles/kg over 2 hours). The increase in urinary
potassium excretion was determined over the sub-
sequent 6 hours (Fig. 2A). Baseline urinary potas-
sium excretion was 55 pEq/min and increased to a
maximum of only 73 .tEq/min as compared with a
greater than twofold increase in control patients.
The response to furosemide was also markedly
blunted (Fig. 2B). This agent increases urinary po-
tassium excretion by augmenting aldosterone secre-
tion, by increasing both distal sodium delivery and
tubular fluid flow. The latter two factors are not de-
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pendent on an increase in aldosterone. The blunted
response to both sodium sulfate and furosemide in
this patient indicates a primary renal tubular potas-
sium secretory defect similar to that found in the 6
patients with sickle cell disease described previous-
ly before [19].
But the patient we are considering here presents
an even more complicated picture, because a defect
in the renin-aldosterone axis also was found. In this
individual, the aldosterone response to angiotensin
II was blunted, and no increase in plasma aldoster-
one occurred following ACTH administration
(Table 2). Following volume contraction with fu-
rosemide and ingestion of a low-sodium diet, the
plasma aldosterone response approximated that of
normal controls (Table 3), but the plasma potassium
concentration at this time was 6.5 mEq/liter. Since
A
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Fig. 2. (A) Top panel. The increase in urinary potassium excre-
tion (UKV) following sodium sulfate infusion in the patient dis-
cussed here (SS) and control subjects. (B) Lower panel. The in-
crease in UKV following furosemide (80 mg orally) in the patient
(SS) and controls. The stipled area represents the range of potas-
sium excretion in the control group. Baseline and maximum peak
rates of UKV are shown in the inserts.
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Table 2. Plasma aldosterone concentration following angiotensin
II and ACTH infusion in the patient with sickle cell disease
discussed here (SS) and in controlsa
Pre-infusion
ng/dl
Post-infusion
ngldl
Angiotensin 11 infusion
Controls 7 3 22 3
SS 8 13
ACTH infusion
Controls 8 2 19 2
SS 14 13
a Control values represent the mean SEM.
Table 3. Plasma aldosterone concentration (ng/dl) and plasma
renin activity (ng of angiotensin generated/mI per hour) following
volume contraction and ambulation in the patient with sickle cell
disease (SS) discussed here and in controlsa
Plasm
aldoster
Controls
a
one
SS
Plasma re
activity
Controls
nm
SS
Baseline 13 2 15 0.6 0.2 0.3
Volume contraction 26 4 26 5.0 1.0 0.6
Volume contraction +
ambulation 66 13 26 11.0 2.0 1.1
Control values represent the mean SEM,
hyperkalemia is the most potent stimulus to aldos-
terone secretion on a chronic basis [11], when this
patient's plasma aldosterone response is viewed in
light of the prevailing plasma potassium concentra-
tion, aldosterone secretion is deficient. The defect
in aldosterone secretion became more obvious
when the subject was ambulated for 2 hours follow-
ing volume depletion. In contrast to the control sub-
jects in whom the plasma aldosterone concentration
rose from 26 to 66 nglml, no increase was observed
in this patient. With regard to plasma renin activity,
both the baseline as well as the stimulated values
were markedly diminished as compared with those
of age-matched controls (Table 3). Thus, the patient
we are discussing here might be considered to have
hyporeninemic hypoaldosteronism" [23]. It
should be pointed out, however, that the plasma a!-
dosterone response to both angiotensin II and
ACTH, substances known to directly stimulate a!-
dosterone secretion [24, 25], was impaired. Most
importantly, persistent hyperkalemia, which nor-
mally provides a potent stimulus to aldosterone se-
cretion [11], also failed to enhance its secretion.
These observations suggest that, even though hypo-
reninemia was present, defects at the level of aldos-
terone biosynthesis, aldosterone release, or both
may have contributed importantly to the hypoal-
dosteronism in this patient.
Before returning to the question of defective al-
dosterone secretion, I would like to review the liter-
ature on the syndrome of hyporeninemic hypoal-
dosteronism."
Review of hyporeninem ic hypoaldosteronisn. To
date, 81 cases of this syndrome have been reported
in the English literature [26—61]. The clinical find-
ings are quite typical (Table 4). The mean age is 65
7 years, with a range from 32 to 82 years. This
observation may be important, as both renin and a!-
dosterone secretion are known to diminish with ad-
vancing age. Approximately 75% of the patients are
asymptomatic, and hyperkalemia is discovered on
routine laboratory screening or during studies for an
unassociated illness. The remainder of the patients
come to medical attention because of symptoms re-
ferable to the hyperkalemia, such as muscle weak-
ness or cardiac arrhythmias. Hyperchioremic meta-
bolic acidosis is found in about 50% of the patients.
Salt wasting is distinctly uncommon; most patients
have a partial defect in aldosterone secretion, but
their plasma aldosterone levels, although reduced,
are sufficient to maintain normal sodium balance
unless the dietary sodium intake is markedly re-
stricted. Even though sodium balance is normal,
however, the low circulating aldosterone levels are
insufficient to prevent hyperkalemia. Baseline corti-
sol levels as well as the cortisol response to ACTH
have been reported as normal in all patients.
Two underlying disorders, chronic renal failure
and diabetes mellitus, are present in such high fre-
quency in this syndrome as to preclude a chance
association. Chronic renal failure was present in 57
of the 81 patients. The types of renal disease are
listed in Table 5; diabetic glomerulosclerosis leads
the list and is followed by a variety of renal diseases
including interstitial nephritis, hypertensive ne-
phropathy, presumed gouty nephropathy, nephroli-
thiasis, analgesic nephropathy, and some others.
The syndrome also has been described in patients
with glomeru!onephritis. Diabetes mellitus was
present in 40 of the 81 patients. We will return to a
possible link between diabetes and hypoaldosteron-
ism later.
I noted with interest that the patient we are dis-
cussing here had hyperuricemia with clinical gout as
well as chronic hypertension. But he had neither a
family history nor clinical or laboratory evidence of
diabetes mellitus. The fasting glucose concentration
was not elevated and an intravenous glucose toler-
ance test was minimally abnormal, but the latter
finding could easily be explained by a combination
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Table 4. Clinical and laboratory characteristics in 81 patients
with the syndrome of hyporeninemic hypoaldosteronism"'
I. Mean age = 65 years; range = 32 to 82 years
2. Findings at presentation:
1. Asymptomatic hyperkalemia (75%)
2. Muscle weakness (25(31
3. Cardiac arrhythmia ' C
4. Hyperchloremic acidosis (-50%)
5. Salt wasting (unusual)
3. Normal glucocorticoid function
4. Mild to moderate renal insufficiency, 57/81 (70%)
5. Diabetes mellitus. 40/81 (49%)
6. Low or low-normal baseline plasma aldosterone levels; all pa-
tients had a subnormal increase following volume con-
traction, 81/81 (100%)
7. Normal baseline and/or stimulated plasma renin leels, 13/74
(18%)
8. Normal aldosterone response to angiotensin 11 infusion, 4/27
(15%)
9. Normal aldosterone response to ACTH administration, 7/34
(2 1%)
a Data taken from Refs. 26—6l.
Table 5. The causes of renal disease in 57 patients with the
syndrome of "hyporeninemic hypoaldosteronism'
Diabetes mellitus 25
Interstitial nephritis" 7
Hypertension 7
Goute 6
Glomerulonephritis 3
Nephrolithiasis 2
Analgesic nephropathy I
Urinary tract obstruction I
Mixed cryoglobulinemia I
Unknown 4
a Data taken from Refs. 26—61.
"Type unspecified
C Gouty nephropathy not documented histologically
of age and renal insufficiency, both of which are as-
sociated with decreased glucose tolerance.
In the 81 reported patients, baseline plasma at-
dosterone concentrations were low or low-normal;
after volume contraction, a subnormal increase oc-
curred in all 81 (Table 4). None of the patients dem-
onstrated an absolute increase close to that ex-
pected for normal subjects. Two studies examined
the effect of normalization of the serum potassium
concentration (by a sodium-potassium exchange
resin) on plasma aldosterone secretion [51, 59]. In
all 11 patients studied, plasma aldosterone levels
fell significantly following reduction of the plasma
potassium concentration. These results emphasize
the importance of relating the plasma aldosterone
level to the plasma potassium concentration. Thus,
although some patients may have low-normal or
even occasionally normal basal plasma aldosterone
levels, these plasma concentrations must be consid-
ered abnormal in the presence of increased plasma
potassium levels.
Reinterpretation of the syndrome. Although this
syndrome has been called "hyporeninemic hypoal-
dosteronism," several lines of evidence suggest
that the primary defect responsible for the hyper-
kalemia in many patients resides in the adrenal
gland and is not related to hyporeninemia (Table 4).
First, baseline renin levels, stimulated renin levels,
or both were normal in 13 of the 74 patients in
whom it was measured. Thus, in at least a sub-
stantial minority of the cases, hypoaldosteronism
cannot be explained on the basis of hyporeninemia.
Second, the response to intravenous angiotensin II
infusion was normal in only 4 of 27 patients. Since
angiotensin II directly stimulates aldosterone re-
lease by the zona glomerulosa [24, 25, 62], the re-
sponse should be normal if the adrenal gland is in-
tact. Likewise, the aldosterone response to ACTH,
another agent that directly stimulates the adrenal
production of aldosterone, was normal in only 7 of
34 patients. Although one could argue that more
prolonged adrenal stimulation—that is, several days
as opposed to a few hours—with angiotensin II and
ACTH is needed to elicit a normal aldosterone re-
sponse because prolonged hyporeninemia had led
to disuse atrophy of the zona glomerulosa, I would
counter the argument by pointing out that nephrec-
tomized patients have normal basal aldosterone lev-
els that increase normally following provocative
stimuli even though these patients have no demon-
strable circulating renin [63—65].
These observations strongly suggest that the syn-
drome of "hyporeninemic hypoaldosteronism" is
of mixed cause. In some patients the hypoaldoste-
ronism is indeed secondary to hyporeninemia. In
others, however, the primary defect probably re-
sides in the adrenal gland. In the absence of suf-
ficient circulating aldosterone, renal potassium ex-
cretion is impaired: the resulting hyperkalemia in
turn suppresses renin secretion [66—68]. If this caus-
al link is correct, prolonged normalization of the
plasma potassium concentration would be expected
to correct the hyporeninemia. whereas aldosterone
levels would remain suppressed. Unfortunately,
this important study has yet to be performed.
A third possibility is that two primary defects ex-
ist: one in the adrenal gland, leading to hypoaldoste-
ronism, and another in the kidney, causing hypo-
reninemia. Resolving this issue would require a pro-
longed study in which the adrenal gland is
stimulated for 7 to 10 days with angiotensin II,
ACTH, or both. If plasma aldosterone levels did not
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increase despite prolonged daily administration of
these agents, one could conclude that a primary ad-
renal defect in aldosterone secretion exists, since
chronic adrenal stimulation with ACTH, angioten-
sin, and hyperkalemia failed to elicit an aldosterone
response. Unfortunately such a study has not been
done.
The hormonal and renal defects that could possi-
bly result in hyperkalemia are summarized in Figure
3 and include: a primary renal defect leading to
decreased renin secretion; a primary adrenal de-
fect in aldosterone biosynthesis, release, or both;
and a primary renal tubular potassium secretory
defect. This figure also provides a possible ex-
planation of why hyperkalemia and hypoaldoste-
ronism are so common in diabetic patients. I should
now like to turn to this problem.
Special characteristics of the diabetic. As dis-
cussed earlier, approximately one-half of the cases
of "hyporeninemic hypoaldosteronism" have oc-
curred in patients with diabetes. We know that in-
sulin stimulates potassium uptake by a variety of
tissues including muscle and liver [69—73]. In addi-
tion, we previously have shown that even basal in-
sulin levels play an important regulatory role in po-
tassium homeostasis: inhibition of basal insulin se-
cretion by as little as 50% results in both a
predictable rise in plasma potassium concentration
and a decreased tolerance to exogenous potassium
[12]. If insulin is also responsible for potassium up-
take by the adrenal gland, then a state of intra-
cellular potassium depletion may exist in diabetic
patients (Fig. 3). Previous studies have shown that
the ability of ACTH and angiotensin II to stimulate
aldosterone secretion by cultured zona glomerulosa
cells is impaired in the presence of low potassium
concentrations [24, 62]. These observations are
consistent with the known stimulatory effect of po-
tassium on the aldosterone biosynthetic pathway,
which involves the conversions of cholesterol to
deoxycorticosterone and corticosterone to aldoste-
rone [25, 74]. Indeed, two recent reports have docu-
mented the presence of acquired enzymatic defects
in aldosterone biosynthesis in diabetic patients [40,
51]. These defects involve deficiencies of both the
18-hydroxylase and 18-dehydrogenase reactions.
Whether the enzymatic defects are secondary to
cellular potassium depletion or some other aspect of
the diabetic state remains to be determined. Be-
cause of discrepant results regarding whether dia-
converting enzyme
Angiotensm I Angiotensin II/
Renin
1 Decreased renin
production Liver
potassium
deplesion
Fig. 3. Schematic representation of potential hormnonal and renal defects resulting in hyperkalemia. Hyperkalemia might result as a
consequence of the following: (I) decreased renin production; (2) decreased aldosterone production despite normal renin secretion
(adrenal defect); (3) a renal tubular secretory defect; (4) insulin deficiency leading to failure of cellular potassium uptake, possibly
involving cells of adrenal zona glomerulosa, and thereby contributing to hypoaldosteronism. (Reprinted with permission of Arch Intern
Mcd 137:842—843, 1977)
2 Adrenal defect
a) loss of responsiveness
b) defective aldosterone
Volume
Hyperkalemia and hyporeninernic hypoaldosteronis,n 125
Time, days
Fig. 4. The effect of deoxycorticosterone acetate (DOCA) on
potassium and sodium balance. Following DOCA administration
(10 mg b.i.d.), the plasma potassium concentration fell from 6.3
to 5.2 mEq/liter with a minimal increase in urinary potassium
excretion and no change in net potassium balance. Despite the
lack of effect of DOCA on urinary potassium excretion, urinary
sodium excretion fell significantly. Dotted lines represent the
dietary intakes of sodium and potassium.
Table 6. Plasma aldosterone and renin responses to tilting in 59
normokalemic diabetic patientsa
Aldosterone N" N
Renin N N
Number 31 5 13 10
Percentage 53% 8% 22% 17%
a Data summarized from Ref. 75.
N = Normal
= Decreased
betics have a primary defect in renin or in aldoste-
rone secretion, deChatel et al studied 59 normoka-
lemic diabetics in an attempt to characterize further
the nature of the defect in the renin-aldosterone axis
[75] (Table 6). In 31 of 59 patients, the renin and
aldosterone responses to tilting were normal. In the
other 28 patients, however, a variety of defects was
observed: 5 had diminished aldosterone responses
with a normal renin response, 13 had impaired renin
release with a normal aldosterone response, and 10
demonstrated impaired release of both renin and al-
dosterone. These results clearly demonstrate that
multiple defects in the renin-aldosterone axis can
occur in diabetic patients and that the hyperkalemia
probably results from a spectrum of disorders.
In addition to a primary adrenal defect in aldoste-
rone production, which leads to diminished renal
potassium excretion, and insulin deficiency, which
results in decreased potassium movement into
cells, hyperkalemia in the diabetic can result from
a variety of other factors (Table 7). Perez et al
and Christlieb et al have demonstrated a high fre-
quency of renal insufficiency in their hyperkalemic
patients who have hypoaldosteronism [52, 55, 61],
but neither group has determined which aspect of
the renal disease—decreased glomerular filtration
rate, interstitial disease with subsequent tubular
dysfunction, or juxtaglomerular scarring with re-
sultant hyporeninism—if any, is the most important
factor contributing to the development of the hyper-
kalemia. As discussed earlier, diminished renal
function rarely leads to impaired renal potassium
excretion unless the glomerular filtration rate is
very low (< 10-15 mI/mm). The glomerular filtra-
tion rates of most of the reported diabetic patients
with hyperkalemia and hypoaldosteronism have ex-
ceeded 20 mI/mm; reduced renal function therefore
is not a convincing explanation for the hyper-
kalemia. Furthermore, de Chatel failed to lind any
correlation between the defect in the renin-angio-
tensin-aldosterone axis and decreased glomerular
filtration rate [75].
In addition to the well-known glomerular
changes, interstitial scarring and tubular atrophy
are prominent features of diabetic nephropathy [76,
77]. Because of accelerated vascular disease, is-
chemic tubular injury and papillary necrosis occur
with increased frequency in the diabetic population
[78]. What role the development of these tubulo-in-
terstitial lesions might play in impaired potassium
excretion is unclear. However, correction of hyper-
kalemia in diabetic patients often requires very
large doses of mineralocorticoids, and reduced
tubular responsiveness thus becomes suspect. We
recently examined the ability of 4 normokalemic pa-
tients with long-standing diabetes to excrete an in-
Table 7. Possible mechanisms contributing to hyperkalemia in
patients with diabetes mellitus
1. Primary adrenal defect in aldosterone production
II. Insulin lack resulting in decreased hepatic and muscle
potassium uptake
111. Renal disease
1. Decreased glomerular filtration rate
2. Interstitial damage leading to a tubular secretory
defect
3. Juxtaglomerular damage leading to hyporeninemia
IV. Inactive ("Rig") renin
V. Decreased catecholamines
VI. Elevated blood volume leading to suppressed renin
VII. Decreased prostaglandin synthesis
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travenous potassium chloride load. Despite a nor-
mal or only slightly decreased giomerular ifitration
rate and an intact renin-aldosterone axis, the in-
crease in urinary potassium excretion was signifi-
cantly impaired in these individuals as compared
with that in control subjects. These preliminary re-
sults, combined with the inability to augment renal
potassium secretion with physiologic doses of mm-
eralocorticoids, raise the possibility that some dia-
betic patients might have a primary defect in tubular
potassium secretion. Finally, Schindler and Som-
mers have postulated that in the diabetic patient,
selective damage to the juxtaglomerular apparatus
by the angiopathic process might lead to a state of
hyporeninemia [79]. Of course, this hypothesis does
not explain the lack of adrenal responsiveness to
chronic hyperkalemia, angiotensin II, and ACTH in
many diabetics.
Recently Day et al and deLeiva et al suggested
another explanation for the high prevalence of hy-
perkalemia in diabetic patients [51, 80]. These au-
thors identified an association between high con-
centrations of the inactive renin precursor "big re-
nm" and reduced levels of plasma renin activity in
diabetic patients (Table 7). This finding raises the
possibility that the hyporeninemia might result from
the impaired conversion of prorenin, or "big re-
nm," to active renin.
Decreased circulating levels of catecholamines
and autonomic neuropathy also have been postulat-
ed as causes of hyporeninemia in diabetic patients
(Table 7). Sympathetic nerve terminals have been
demonstrated in the juxtagiomerular apparatus [81],
and epinephrine has been shown to stimulate renal
secretion [82]. Because autonomic neuropathy is
common in diabetes, and because patients with
long-standing diabetes have decreased circulating
levels of catecholamines [83], decreased sympathet-
ic activity has been postulated as a cause of the
hyporeninemia. Support for this hypothesis comes
from a recent report by Tuck et al, who found a
decreased plasma renin response to isoproterenol in
5 hyperkalemic diabetics who had hyporeninemic
hypoaldosteronism" as well as autonomic or pe-
ripheral neuropathy or both [84]. However, plasma
and/or urinary catecholamines were normal in all 6
previously studied patients with "hyporeninemic
hypoaldosteronism" [34, 35, 43, 44], and no relation
between decreased plasma epinephrine levels and
defects in the renin-aldosterone axis was detected
in 59 diabetic patients [75]. It seems possible never-
theless that, at least in some diabetics, decreased
sympathetic nervous system activity, low circulat-
ing plasma epinephrine levels, or both might con-
tribute to hyporeninemia. How frequently this
mechanism is responsible, however, remains to be
determined.
Other possible explanations jr renin suppres-
sion. Oh et al postulated that extracellular fluid vol-
ume expansion secondary to sodium retention is re-
sponsible for a state of physiologic renin suppres-
sion in the hyporeninemic hypoaldosteronism"
syndrome [46]. However, none of the patients re-
ported showed a normal aldosterone response to
volume contraction that had been induced with di-
uretics, a low-sodium diet, or both. A two- to three-
fold increase in plasma aldosterone levels was ob-
served in many patients, but the absolute values
were always well below those reported in healthy
controls with an equivalent degree of volume con-
traction. Oh et al reported patients whose plasma
renin activity rose into the normal range following
volume contraction for 3 to 6 weeks, but whose
plasma aldosterone levels, although significantly in-
creased, remained below normal. The dispropor-
tionate increase in plasma renin as compared to
plasma aldosterone levels in this study is another
observation that points to a primary adrenal defect
in aldosterone secretion.
Finally, decreaed circulating concentrations of
prostaglandins have been suggested as a cause of
hyporeninemic hypoaldosteronism." Prostaglan-
din E2 is known to stimulate renin release [85]; the
administration of prostaglandin synthesis inhibitors
impairs renin release [86, 87]. Some prostaglandins,
E1 and E2, also stimulate aldosterone and corticos-
terone synthesis in vitro [88]. Recently, hyper-
kalemia was observed in association with hypore-
ninemia and hypoaldosteronism in a 28-year-old
woman treated with indomethacin [89]. Both the
hyperkalemia and the impairment of the renin-al-
dosterone axis were corrected after withdrawal of
indomethacin; both recurred when treatment with
indomethacin was resumed. Two subsequent stud-
ies have demonstrated diminished urinary prosta-
glandin E levels in patients with the "hyporenin-
emic hypoaldosteronism" syndrome [58, 90], but
this observation has been refuted by other reports
[91, 92]. Although the possible association between
prostaglandin deficiency and hyporeninemic hy-
poaldosteronism" is interesting, further studies are
needed to clarify these conflicting observations.
Management of hyperkalernia. Once the diagno-
sis of hypoaldosteronism has been established, sev-
eral different therapeutic regimens can be employed
to lower the plasma potassium concentration. The
physician should keep in mind, however, that the
majority of patients suffering from this syndrome
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Table 8. Possible modalities of therapy in patients with
hyperkalemia and hypoaldosteronism
I. Mineralocorticoids: 43/51, 84% responded
1. Large doses often required
2. Urinary potassium excretion does not always increase
despite normalization of plasma potassium levels
II. Diuretics
III. Sodium bicarbonate
IV. Sodium polystyrene sulfonate
V. No therapy
VI. Avoid drugs that predispose to hyperkalemia
1. Spironolactone
2. Triamterene
3. Amiloride
4. Heparin
5. Indomethacin
6. Propranolol?
VII. Avoid volume contraction
Data taken from Refs. 26—61.
are elderly and have associated medical complica-
tions such as diabetes mellitus, atherosclerotic car-
diovascular disease, chronic renal failure, and hy-
pertension. Caution should be taken therefore to
ensure that the side effects of therapy do not out-
weigh the benefits of correcting the hyperkalemia.
Mineralocorticoid replacement, usually given as
fludrocortisone acetate, is the mainstay of therapy
(Table 8). Studies of 51 patients treated with a mm-
eralocorticoid report a reduction of the plasma po-
tassium concentration in 43, but large doses of the
steroid, often as high as 0.4 to 1.0 mg daily, were
frequently required to reduce the plasma level to
normal [26-61]. As indicated above, this observa-
tion suggests that the renal tubular cell is resistant
to the action of mineralocorticoids, at least with re-
spect to their effect on potassium secretion. Sensi-
tivity to the sodium-retentive effects of fludrocorti-
sone appeared to be less affected, because marked
sodium retention with edema, exacerbation of hy-
pertension, and congestive heart failure were com-
mon consequences. In many patients the adminis-
tration of a loop diuretic was required to prevent or
treat these complications.
The patient presented today underwent a trial of
deoxycorticosterone acetate (DOCA), 10 mg twice
a day, under metabolic balance conditions; the re-
sults of treatment are shown in Figure 4. The dotted
lines represent the dietary sodium and potassium in-
take. During the 3 days prior to DOCA administra-
tion, the plasma potassium concentration was 6.3
mEq/liter, and the potassium excretion in both the
urine and stool approximated the dietary potassium
intake. Following DOCA administration, the
plasma potassium concentration fell to 5.2 mEq/lit-
er, but this improvement was associated with a
weight gain and a worsening of hypertension. Be-
cause of the plasma potassium response to DOCA,
the patient was started on fludrocortisone acetate;
at a dose of 0.4 mglday the potassium concentration
ranged from 4.9 to 5.2 mEq/liter. However, treat-
ment was again associated with marked sodium re-
tention and a 7 kg weight gain that was difficult to
control even with large doses of furosemide. Final-
ly, fludrocortisone was discontinued because the
patient developed congestive heart failure. An in-
teresting aspect of this patient's initial response to
DOCA was that his plasma potassium concentra-
tion fell without a significant increase in net potas-
sium excretion. Urinary potassium excretion did in-
crease slightly on DOCA, but this small increase
could not account for the progressive decline in the
plasma potassium concentration. More important-
ly, the net potassium balance did not change; this
finding suggests that the mineralocorticoid primari-
ly increased the movement of potassium from the
extracellular to the intracellular compartment.
Four previous reports also document correction
of hyperkalemia by mineralocorticoid therapy in pa-
tients with "hyporeninemic hypoaldosteronism"
without a concomitant increase in urinary potas-
sium excretion [32, 33, 54, 58]. This observation is
consistent with the known effect of aldosterone on
extrarenal potassium homeostasis [93, 94]. These
reports and the response of the patient under dis-
cussion underscore the existence of tubular unre-
sponsiveness, which has not previously been em-
phasized in this syndrome. Whether this tubular de-
fect in potassium secretion is related to the
underlying renal disease in most of these patients or
to some other as yet unrecognized factor remains to
be determined.
If the hyperkalemia fails to respond to fludro-
cortisone acetate or if excessive sodium retention is
encountered, a trial of potassium-wasting diuretics
is warranted. In many patients, particularly those
with a primary tubular potassium secretory defect,
thiazide diuretics are effective [95]. Sodium bi-
carbonate may improve potassium excretion and
correct the hyperkalemia in some patients. In this
setting, the kaliuresis is probably caused by many
factors including increased luminal negativity of
the distal tubule. The presence in the lumen of the
poorly reabsorbable bicarbonate anion, increased
delivery of sodium to the distal tubule, and a direct
stimulatory effect of alkalosis on distal potassium
secretion all combine to produce the kaliuresis. The
increase in blood pH and bicarbonate concentration
also helps shift potassium into cells. If these mea-
sures fail, one can always employ a sodium-potas-
sium exchange resin such as sodium polystyrene
128 Nephrology Forum
Fig. 5. Postnortem exa,ninalion of the kidneys of the patient discussed here. Panel A, light microscopy: The glomeruli are hypercellular
with mesangial cell proliferation and an increase in mesangial matrix. Panel B, light microscopy: The interstitium shows extensive
scarring and tubular atrophy. Some postmortem autolysis also is present. Panels C and D, electron microscopy: There is thickening of
the glomerular basement membrane by electron-dense deposits that extend into the mesangium (see arrows). The tubular basement
membranes are extremely thickened by the diffuse deposition of electron-dense deposits (see arrows).
sulfonate. In my experience, however, most pa-
tients have found this medication difficult to toler-
ate. In many patients, particularly those with only
mild to moderate hyperkalemia, 5.0 to 5.6 mEqilit-
er, it is often best to institute no therapy and period-
ically check the plasma potassium concentration to
ensure that the hyperkalemia has not reached dan-
gerous levels. In all patients, drugs known to impair
renal potassium excretion should be avoided (Table
8). Volume contraction, which decreases distal so-
dium delivery, also should be prevented.
A speculative thought. There are many other in-
teresting features of this case, but rather than try to
consider them all, I would like to end on a provoca-
tive note and propose still another explanation for
the hyperkalemia in this patient. The patient recent-
ly succumbed at age 71 from a massive stroke. Post-
mortem examination of the kidneys revealed large
glomeruli containing sickled red blood cells. An in-
crease in mesangial cellularity and mesangial matrix
was present, with thickening of the capillary loops,
extensive interstitial fibrosis, and tubular atrophy.
Electron microscopy revealed thickened glomerular
basement membranes with electron-dense deposits
and mesangial proliferative changes. Numerous
electron-dense deposits within the tubular base-
ment membranes were apparent also (Fig. 5). These
pathologic findings are similar to those reported by
Pardo et al., who studied 7 patients with sickle cell
disease and found renal tubular antigen-antibody
complexes in the plasma and kidneys [96]. I wonder
whether it is possible that this patient's impairment
of renal tubular potassium secretion resulted from
antibodies directed at the tubular basement mem-
:
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brane, as has been demonstrated in patients with
systemic lupus erythematosus [97, 98]?
Questions and Answers
DR. JAMES MELBY (Professor of Medicine, Boston
University School of Medicine, Chief, Endocrinolo-
gy Division, University Hospital, Boston, Massa-
chusetts): As you suggested, it appears that at least
some cases of hypoaldosteronism are due to a pri-
mary adrenocortical disorder. As you know, our
own observations in colloboration with the Christ-
lieb group at the Joslin Clinic suggest that at least 2
patients have had primary corticosterone methyl
oxidase deficiencies [51]. One patient appeared to
have corticosterone methyl oxidase deficiency
Type I in which the precursor, corticosterone, was
overabundant. In the other patient, who had corti-
costerone methyl oxidase deficiency Type II, the
by-product, 1 8-hydroxycorticosterone, appeared in
excess. The defect can be amplified markedly by
the administration of ACTH. We wondered wheth-
er the presence of big renin had anything to do with
the biosynthetic defects we observed, but thus far
we have been unable to relate circulating levels of
big renin to inhibition of the enzymes involved in
the oxidation of corticosterone to aldosterone.
The role of potassium is even more difficult to ex-
plain in patients with hypoaldosteronism. Potas-
sium stimulates aldosterone biosynthesis at both an
early and a late stage. There is also some suggestion
that potassium stimulation of the conversion of cho-
lesterol to aldosterone precursors is unimpaired in
hypoaldosteronism but that potassium stimulation
of corticosterone methyl oxidation is impaired.
DR. DEFRONZO: One of the ways to answer that
question would be to culture zona glomerulosa cells
in the presence of insulin to define whether potas-
sium uptake is insulin dependent as it is in muscle
and liver tissue. If it is, I think one could argue
strongly that in the absence of insulin, a state of in-
tracellular potassium depletion exists and that this
depletion could account for the abnormalities in al-
dosterone biosynthesis observed in vivo [25, 74].
DR. COHEN: You stated that in studies with cul-
tured zona glomerulosa cells, the low potassium
concentration counteracted the stimulation of a!-
dosterone secretion by angiotensin II and ACTH.
Were those studies performed in the absence of in-
sulin? If so, doesn't that suggest that the potassium
entry step is not dependent on insulin?
DR. DEFRONZO: Yes, those studies were carried
out in the absence of insulin. However, if one exam-
ines the dose-response curve, one finds that obtain-
ing a maximum aldosterone response to angiotensin
II and to ACTH requires concentrations of potas-
sium greater than 5 mEq/liter [24, 62]. Perhaps if
insulin were added to the medium, a maximum re-
sponse could be achieved with concentrations in the
physiologic range.
I would like to ask Dr. Melby a question. Do you
think that prostaglandin deficiency plays any role in
the impaired renin-aldosterone response in this het-
erogeneous group of patients? Recently, several re-
ports have appeared that suggest a role for prosta-
glandin E deficiency in this syndrome [58, 89, 90].
What is known about the effects of prostaglandin on
the enzymatic steps involved in steroidogenesis?
DR. MELBY: We have found no evidence for this
except in one paper by Saruta and Kaplan, who
found that prostaglandins affect aldosterone secre-
tion; in that study, superphysiologic amounts of
PGE2 were used [99]. I would like to suggest anoth-
er explanation.
Recently, many papers have examined the regu-
lation of adrenal aldosterone secretion by dopa-
mine. Dopamine tonically inhibits aldosterone se-
cretion, and receptors for dopamine are present in
the adrenal cortex. As a matter of fact, in some pa-
tients with autonomic insufficiency, the dopamine-
to-norepinephrine ratio changes. Whether dopa-
mine excess is involved in hypoaldosteronism I
don't know, but it is tempting to speculate about it.
The prostaglandin question is confusing. As I un-
derstand it, prostaglandin deficiency would prob-
ably lead to decreased renin secretion and not di-
rectly affect aldosterone secretion.
DR. DEFRONZO: I can't comment directly on the
role of dopamine, but there is some additional new
information on the effect of prostaglandins on the
renin-angiotensin system. Tan and Muirow exam-
ined the ability of furosemide to stimulate plasma
renin activity and plasma aldosterone secretion in a
group of normal volunteers before and after receiv-
ing indomethacin, a prostaglandin synthetase inhib-
itor [100]. A marked inhibition of both the renin and
aldosterone response was found. On the basis of
these studies, the authors postulated that prostaglan-
din deficiency plays an important role in the syn-
drome of hyporeninemic hypoaldosteronism. It is
unclear, however, whether the changes were due to
a vascular phenomenon or to inhibition of some en-
zymatic step in renin biosynthesis, aldosterone bio-
synthesis, or both.
DR. CLARK SAWIN (Chief, Endocrine-Diabetes
Section, VA Hospilal, Boston, Massachusetts):
First, I thoroughly support your idea that many fac-
tors are involved in the pathogenesis of hyporeni-
nemic hypoaldosteronism. I also concur with your
observations that large doses of mineralocorticoids
are often necessary in the treatment of these pa-
tients. As you pointed out, many patients get into
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difficulty because of sodium excess when treated in-
discriminately with fludrocortisone, and the drug
therefore must be used with great caution. Second,
I would like to know whether there are sufficient
data in normal individuals, especially data cor-
rected for age, that enable one to interpret renin and
aldosterone values under a variety of conditions.
The published literature does not have a great deal
of information on this.
DR. DEFRONZO: In answer to Dr. Sawin's ques-
tion, I would like to note that the controls for all of
the studies discussed today were age-matched. In
our study of potassium homeostasis in patients with
sickle cell disease, the mean age of the control pop-
ulation was 23 years and was similar to that of the
sickle cell patients [19]. Furthermore, for all com-
parisons with the patient discussed today, a sepa-
rate group of older individuals was used to establish
control values. So, I think it is safe to say that renin
levels decrease as a function of age but the values in
this elderly patient were even lower than in age-
matched controls.
DR. SAwIN: One final question—You pointed out
that this patient had a substantial rise in his aldoste-
rone level following volume contraction but that it
did not rise as much as in normal controls. Did the
serum potassium level change during that interval?
DR. DEFRONZO: The serum potassium level fell
slightly, from 6.7 to 6.5 mEq/liter. This was prob-
ably due to the administration of furosemide, which
was used to induce the volume contraction. In most
of the reported cases of hyporeninemic hypoal-
dosteronism, plasma renin and aldosterone levels
rose following volume contraction, but the rise is
markedly blunted. In one study, the aldosterone
level rose by two- to threefold and it was defined as
a normal response [46]. However, since the basal
plasma aldosterone level was very low, the absolute
increase in plasma aldosterone concentration was
significantly impaired as compared to normal con-
trols. In this situation, I think it is misleading to
look at the percentage increase in plasma aldoste-
rone above the basal level rather than at the abso-
lute values.
DR. W. B. SCHWARTZ (Professor of Medicine,
Tufts University School of Medicine): How likely do
you think it is that an atrophic adrenal gland might
not respond to acute stimulation but might respond
after several days of stimulation?
DR. DEFRONZO: I think this is a possibility that
needs to be examined, as I tried to emphasize in my
discussion. To prove that the aldosterone response
to angiotensin II and to ACTH is blunted, those
hormones should be given for at least 3 to 4 con-
secutive days. However, I would like to emphasize
that the most potent stimulus to aldosterone secre-
tion when present on a chronic basis is hyper-
kalemia. McCaa et al. have shown that if you in-
crease the serum potassium level by as little as 0.3
to 0.5 mEq/liter, aldosterone levels will increase
significantly and will remain elevated despite a re-
turn of the serum potassium concentration to nor-
mal [11]. The patient today had a serum potassium
level that was persistently elevated to greater than 6
mEq/liter, yet his aldosterone response was still im-
paired.
DR. SCHWARTZ: Would you say therefore that it
is extremely unlikely that even sustained ACTH or
angiotensin II administration would produce an in-
crease in aldosterone secretion?
DR. DEFRONZO: I think that in those patients in
whom the defect lies in the adrenal gland, it will not
make any difference how much ACTH or angioten-
sin II is given. However, one might expect a dif-
ferent result if the defect is secondary to impaired
renin secretion. Here, chronic stimulation with an-
giotensin II or ACTH might be necessary to elicit a
normal aldosterone response.
DR. COHEN: That seems inconsistent to me. If the
problem were at the level of secretion and if the ad-
renal glands were inherently normal, why wouldn't
the persistent hyperkalemia stimulate aldosterone
secretion?
DR. DEFRONZO: I don't know, unless, of course,
multiple defects exist, as I suspect.
DR. MELBY: We are studying a large number of
individuals from Amish families in Hershey, Penn-
sylvania. One infant of one of these families has
clinically evident hypoaldosteronism with salt wast-
ing and hyperkalemia [101]. He has an inherited
corticosterone methyloxidase deficiency Type II,
with elevated blood 18-hydroxycorticosterone lev-
els and depressed plasma aldosterone levels. The
defect is probably inherited in an autosomal reces-
sive fashion. These patients might compensate for
their deficiency by raising their renin activity. As
these patients are only occasionally hyperkalemic, I
believe that multiple defects must be involved be-
cause of this ability to compensate.
DR. DEFRONZO: Your findings are similar to what
has been described in Iranian Jews, in whom a par-
tial aldosterone biosynthetic defect also appears to
be present [102]. Those patients have normal
plasma aldosterone concentrations at the expense
of markedly elevated plasma renin levels. They can
excrete their daily intake of potassium normally but
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they require increased plasma potassium levels to
do so.
DR. COHEN: Hyponatremia is another potent
stimulus to aldosterone secretion [103], which
might in theory be used as a provocative test. Do
you know whether anyone has ever attempted to
use this stimulus to evaluate adrenal function?
DR. DEFRONZO: From a practical standpoint that
would be difficult because one would have to de-
crease the serum sodium concentration by at least
10 mEq/liter to stimulate aldosterone secretion
[104]. I think that this would be difficult to carry out
without changing the volume status of the patient.
As far as I know, hyponatremia has not been used
as a provocative stimulus.
DR. HARRINGTON: Were any abnormalities found
in the adrenal gland at this patient's autopsy?
DR. DEFRONZO: Unfortunately, the adrenal
glands from this patient were not recovered for ex-
amination post mortem.
DR. HARRINGTON: Are there any systematic
studies of adrenal gland morphology in patients
with hyporeninemic hypoaldosteronism or sickle
cell disease?
DR. DEFRONZO: Of the 81 patients reported with
this syndrome, adrenal histology has been looked at
in 5. In one patient, the adrenal was described as
atrophic, but in none were any significant histologic
changes observed by light microscopy. I do not
know of any reports describing abnormalities in ad-
renal pathology in patients with sickle cell disease,
but this question has not been examined in a sys-
tematic fashion.
DR. MARK MOLITCH (Endocrinology Division,
NEMCH): You mentioned that impaired tubular po-
tassium secretion might occur in patients with lupus
nephritis. Have you seen any patients with lupus
who had hyporeninemic hypoaldosteronism?
DR. DEFR0NzO: No, the two patients that we re-
ported previously both had normal renin and al-
dosterone responses. However, both had an im-
paired ability to augment potassium excretion in re-
sponse to sodium sulfate and furosemide [98].
DR. M0LITcH: We have been interested in a small
number of patients who develop a modest hyper-
chloremic acidosis in the recovery phase following
ketoacidosis. I wonder whether those patients have
renal tubular disease or hyporeninemic hypoal-
dosteronism, perhaps due to volume overload in the
recovery period.
DR. DEFRONZO: Oh et a!. reported the frequent
development of hyperchloremic acidosis during the
treatment of 35 diabetic patients with ketoacidosis
[105]. They did not directly examine renal acid-
ification, however. One well-documented case of
hyperkalemia and hyporeninemic hypoaldosteron-
ism developing secondary to volume overload has
been reported [106]. That patient consumed mas-
sive doses of sodium bicarbonate as baking soda for
epigastric discomfort and developed hyperkalemia.
When the sodium bicarbonate therapy was stopped,
the plasma renin and aldosterone levels, which
were low, rose and the hyperkalemia disappeared.
The authors postulated that the chronic state of vol-
ume expansion was responsible for the aldosterone
and renin suppression. I think this is an uncommon
occurrence, however.
DR. KASSIRER: Long before the syndrome of
hyporenine mic hypoaldosteronism was described,
we recognized patients with mild renal insufficiency
who had hyperchioremic acidosis and hyperkale-
mia. Typically these patients had some form of
tubulointerstitial renal disease. What is your opin-
ion of such patients, that is, nondiabetics with mild
renal insufficiency? Do some have renal tubular dis-
ease only and others have hyporeninemic hypoal-
dosteronism?
DR. DEFRONZO: I do think that these patients fall
into two separate groups. In some, renal interstitial
disease results in tubular injury and a permanent
tubular defect in potassium and hydrogen ion secre-
tion despite normal plasma renin and aldosterone
levels. In others, a so-called Type IV renal tubular
acidosis is probably present. In this latter group, it
has been postulated that an interstitial disease pro-
cess injures the juxtaglomerular apparatus leading
to hyporeninemia and eventually to hypoaldoste-
ronism. The development of hypoaldosteronism is
responsible, then, for the defect in both potassium
and hydrogen ion secretion. In this context, the
acid-base status of patients with hyporeninemic hy-
poaldosteronism is of interest. Of the published cas-
es, approximately one-half have hyperchioremic
metabolic acidosis. The data in the literature con-
cerning the influence of aldosterone on renal acid-
ification are somewhat controversial [57, 107]. Se-
bastian et al. treated 4 such patients with fludrocorti-
sone and reported that renal acidification returned
to normal and that the hyperchloremic acidosis was
corrected [57].
DR. COHEN: I think that study is hard to inter-
pret. When those patients were given fludrocorti-
sone, they were also ingesting a normal salt diet and
hence almost certainly experienced positive sodium
balance. We know from studies of chronic hydro-
chloric acid acidosis in the dog that DOCA-induced
132 Nephro/ogy Forum
volume expansion stimulates acid excretion but that
DOCA alone-that is, without volume expansion-
does not [108].
DR. DEFRONZO: A recent study by Hulter et al.
has examined the role of aldosterone in renal acid-
ification in a more controlled fashion utilizing the
adrenalectomized dog model [109]. The authors
conclude that a lack of aldosterone leads to an im-
pairment in renal acidification and ammonia excre-
tion.
DR. A. LEVEY (Renal Fellow, NEMCH): Do you
think that this patient's sympathectomy played any
role in the genesis of the hyperkalemia?
DR. DEFRONZO: It is likely that the sympathetic
nervous system is important in maintaining basal re-
nm levels. Also, it is known that catecholamines are
a provocative stimulus for renin secretion. Thus, I
think the sympathectomy could have played some
role in the development of the hyporeninemia. Al-
though the sympathectomy was performed long be-
fore the hyperkalemia developed, nevertheless it
may have been an underlying factor just as age was.
The role of the sympathetic nervous system and de-
creased circulating epinephrine levels in the devel-
opment of the hyporeninemic hypoaldosteronism
syndrome clearly deserves to be examined in a
more systematic pattern.
Reprint requests to Dr. Ralph DeFronzo, Yale University
School of Medicine, 333 Cedar Street, New Haven, Connecticut
065/0, USA
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